#BEGIN_DRUGCARD DB00720

# AHFS_Codes:
92:00.00

# ATC_Codes:
M05BA02

# Absorption:
After oral administration, absorption is estimated at 1&ndash;3% of the ingested dose because of the low uptake from the gastrointestinal tract.

# Biotransformation:
Clodronate is not metabolized in humans.

# Brand_Mixtures:
Not Available

# Brand_Names:
Acide Clodronique [INN-French]
Acido Clodronico [INN-Spanish]
Acidum Clodronicum [INN-Latin]
Bonefos
Clasteon
Dichloromethanediphosphonic acid
Dichloromethylidene diphosphonate
Loron
Ostac

# CAS_Registry_Number:
10596-23-3

# ChEBI_ID:
110423

# Chemical_Formula:
CH4Cl2O6P2

# Chemical_IUPAC_Name:
[dichloro(phosphono)methyl]phosphonic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
1984837

# Description:
A diphosphonate which affects calcium metabolism. It inhibits bone resorption and soft tissue calcification. [PubChem]

# Dosage_Forms:
Capsule	Oral
Solution	Intravenous
Solution	Intravenous

# Drug_Category:
Antihypocalcemic Agents
Antineoplastic Agents
Bisphosphonates
Bone Density Conservation Agents
Osteoporosis Prophylactic

# Drug_Interactions:
Aluminium	Formation of non-absorbable complexes
Calcium	Formation of non-absorbable complexes
Calcium Acetate	Calcium Salts may decrease the serum concentration of Bisphosphonate Derivatives such as clodronate. Avoid administration of oral calcium supplements within 2 hours before or after tiludronate/clodronate/etidronate.
Calcium Chloride	Calcium salts may decrease the serum concentration of bisphosphonate derivatives. Avoid administration of oral calcium supplements within 2 hours before or after tiludronate/clodronate/etidronate.
Dihydroxyaluminium	Formation of non-absorbable complexes
Estramustine	Clodronate may increase the levels of estramustine.
Iron	Formation of non-absorbable complexes
Iron Dextran	Formation of non-absorbable complexes
Magnesium	Formation of non-absorbable complexes
Magnesium oxide	Formation of non-absorbable complexes
Sucralfate	Formation of non-absorbable complexes

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Investigational
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
-2.4

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
395 mg/L

# Food_Interactions:
Food decreases absorption. Take on an empty stomach.

# GenBank_ID:
Not Available

# Generic_Name:
Clodronate

# HET_ID:
Not Available

# Half_Life:
Approximately 13 hours.

# InChI_Identifier:
InChI=1S/CH4Cl2O6P2/c2-1(3,10(4,5)6)11(7,8)9/h(H2,4,5,6)(H2,7,8,9)

# InChI_Key:
InChIKey=ACSIXWWBWUQEHA-UHFFFAOYSA-N

# Indication:
For the management of hypercalcemia of malignancy and as an adjunct in the management of osteolysis resulting from bone metastases of malignant tumors.

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
720

# Mechanism_Of_Action:
The bisphosphonate group binds strongly to the bone mineral, hydroxyapatite. This explains the specific pharmacological action of these compounds on mineralized tissues, especially bone. The exact mechanism of action of clodronate is not known, however it is known that it does not inhibit protein isoprenylation but can be metabolized intracellularly to a &beta;-&gamma;-methylene (AppCp-type) analog of ATP (AppCCl2p), which is cytotoxic to macrophages in vitro. Inhibition of the ADP/ATP translocase by the metabolite AppCCl2p is a likely route by which clodronate causes osteoclast apoptosis and inhibits bone resorption. Recently, the slime mold <i>Dictyostelium discoideum</i> was shown to take up bisphosphonates by pinocytosis. In these cells, clodronate, but not other pharmacologically active bisphosphonates, was incorporated into adenine nucleotides, which could potentially explain why this bisphosphonate sometimes seems to act differently than the other bisphosphonates. Clodronate, like all biphosphonates, also binds protein-tyrosine-phosphatase.

# Melting_Point:
250 Â°C

# Molecular_Weight_Avg:
244.892

# Molecular_Weight_Mono:
243.886016298

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA10239

# Pharmacology:
Clodronate is a first generation (non-nitrogenous) bisphosphonate in the same family as etidronate and tiludronate. Clodronate affects calcium metabolism and inhibits bone resorption and soft tissue calcification. Of the clodronate that is resorbed (from oral preparation) or infused (for intravenous drugs), about 50% is excreted unchanged by the kidney. The remainder has a very high affinity for bone tissue, and is rapidly absorbed onto the bone surface. Clodronate has been shown to prevent or delay skeletal-related events and decrease bone pain as well as normalize calcium levels in the presence of hypercalcemia.

# Predicted_LogP_Hydrophobicity:
0.16

# Predicted_LogS:
-1.5

# Predicted_Water_Solubility:
7.47e+00 g/l

# Primary_Accession_No:
DB00720

# Protein_Binding:
2%-36%

# PubChem_Compound_ID:
25419

# PubChem_Substance_ID:
46508646

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
APRD00639

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
OP(O)(=O)C(Cl)(Cl)P(O)(O)=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Decreases in serum calcium following substantial overdosage may be expected in some patients. Signs and symptoms of hypocalcemia also may occur in some of these patients.

# Update_Date:
2013-02-08 16:19:35 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Clodronate

# pKa_Isoelectric_Point:
Not Available

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
PTGS2

# Phase_1_Metabolizing_Enzyme_1_ID:
290

# Phase_1_Metabolizing_Enzyme_1_Name:
Prostaglandin G/H synthase 2

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>Prostaglandin G/H synthase 2 precursor
MLARALLLCAVLALSHTANPCCSHPCQNRGVCMSVGFDQYKCDCTRTGFYGENCSTPEFL
TRIKLFLKPTPNTVHYILTHFKGFWNVVNNIPFLRNAIMSYVLTSRSHLIDSPPTYNADY
GYKSWEAFSNLSYYTRALPPVPDDCPTPLGVKGKKQLPDSNEIVEKLLLRRKFIPDPQGS
NMMFAFFAQHFTHQFFKTDHKRGPAFTNGLGHGVDLNHIYGETLARQRKLRLFKDGKMKY
QIIDGEMYPPTVKDTQAEMIYPPQVPEHLRFAVGQEVFGLVPGLMMYATIWLREHNRVCD
VLKQEHPEWGDEQLFQTSRLILIGETIKIVIEDYVQHLSGYHFKLKFDPELLFNKQFQYQ
NRIAAEFNTLYHWHPLLPDTFQIHDQKYNYQQFIYNNSILLEHGITQFVESFTRQIAGRV
AGGRNVPPAVQKVSQASIDQSRQMKYQSFNEYRKRFMLKPYESFEELTGEKEMSAELEAL
YGDIDAVELYPALLVEKPRPDAIFGETMVEVGAPFSLKGLMGNVICSPAYWKPSTFGGEV
GFQIINTASIQSLICNNVKGCPFTSFSVPDPELIKTVTINASSSRSGLDDINPTVLLKER
STEL

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P35354

# Drug_Target_1_Cellular_Location:
Mitochondrion
mitochondrial inner membrane
multi-pass membrane protein

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
11752352	Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
11961144	Lehenkari PP, Kellinsalmi M, Napankangas JP, Ylitalo KV, Monkkonen J, Rogers MJ, Azhayev A, Vaananen HK, Hassinen IE: Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol Pharmacol. 2002 May;61(5):1255-62.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
SLC25A4

# Drug_Target_1_GenBank_ID_Gene:
J02966

# Drug_Target_1_GenBank_ID_Protein:
339920

# Drug_Target_1_GeneCard_ID:
SLC25A4

# Drug_Target_1_Gene_Name:
SLC25A4

# Drug_Target_1_Gene_Sequence:
>894 bp
ATGGGTGATCACGCTTGGAGCTTCCTAAAGGACTTCCTGGCCGGGGCGGTCGCCGCTGCC
GTCTCCAAGACCGCGGTCGCCCCCATCGAGAGGGTCAAACTGCTGCTGCAGGTCCAGCAT
GCCAGCAAACAGATCAGTGCTGAGAAGCAGTACAAAGGGATCATTGATTGTGTGGTGAGA
ATCCCTAAGGAGCAGGGCTTCCTCTCCTTCTGGAGGGGTAACCTGGCCAACGTGATCCGT
TACTTCCCCACCCAAGCTCTCAACTTCGCCTTCAAGGACAAGTACAAGCAGCTCTTCTTA
GGGGGTGTGGATCGGCATAAGCAGTTCTGGCGCTACTTTGCTGGTAACCTGGCGTCCGGT
GGGGCCGCTGGGGCCACCTCCCTTTGCTTTGTCTACCCGCTGGACTTTGCTAGGACCAGG
TTGGCTGCTGATGTGGGCAGGCGCGCCCAGCGTGAGTTCCATGGTCTGGGCGACTGTATC
ATCAAGATCTTCAAGTCTGATGGCCTGAGGGGGCTCTACCAGGGTTTCAACGTCTCTGTC
CAAGGCATCATTATCTATAGAGCTGCCTACTTCGGAGTCTATGATACTGCCAAGGGGATG
CTGCCTGACCCCAAGAACGTGCACATTTTTGTGAGCTGGATGATTGCCCAGAGTGTGACG
GCAGTCGCAGGGCTGCTGTCCTACCCCTTTGACACTGTTCGTCGTAGAATGATGATGCAG
TCCGGCCGGAAAGGGGCCGATATTATGTACACGGGGACAGTTGACTGCTGGAGGAAGATT
GCAAAAGACGAAGGAGCCAAGGCCTTCTTCAAAGGTGCCTGGTCCAATGTGCTGAGAGGC
ATGGGCGGTGCTTTTGTATTGGTGTTGTATGATGAGATCAAAAAATATGTCTAA

# Drug_Target_1_General_Function:
Involved in nucleotide transporter activity

# Drug_Target_1_General_References:
10926541	Kaukonen J, Juselius JK, Tiranti V, Kyttala A, Zeviani M, Comi GP, Keranen S, Peltonen L, Suomalainen A: Role of adenine nucleotide translocator 1 in mtDNA maintenance. Science. 2000 Aug 4;289(5480):782-5.
11756613	Napoli L, Bordoni A, Zeviani M, Hadjigeorgiou GM, Sciacco M, Tiranti V, Terentiou A, Moggio M, Papadimitriou A, Scarlato G, Comi GP: A novel missense adenine nucleotide translocator-1 gene mutation in a Greek adPEO family. Neurology. 2001 Dec 26;57(12):2295-8.
12112115	Komaki H, Fukazawa T, Houzen H, Yoshida K, Nonaka I, Goto Y: A novel D104G mutation in the adenine nucleotide translocator 1 gene in autosomal dominant progressive external ophthalmoplegia patients with mitochondrial DNA with multiple deletions. Ann Neurol. 2002 May;51(5):645-8.
2541251	Cozens AL, Runswick MJ, Walker JE: DNA sequences of two expressed nuclear genes for human mitochondrial ADP/ATP translocase. J Mol Biol. 1989 Mar 20;206(2):261-80.
2547778	Li K, Warner CK, Hodge JA, Minoshima S, Kudoh J, Fukuyama R, Maekawa M, Shimizu Y, Shimizu N, Wallace DC: A human muscle adenine nucleotide translocator gene has four exons, is located on chromosome 4, and is differentially expressed. J Biol Chem. 1989 Aug 25;264(24):13998-4004.
2823266	Neckelmann N, Li K, Wade RP, Shuster R, Wallace DC: cDNA sequence of a human skeletal muscle ADP/ATP translocator: lack of a leader peptide, divergence from a fibroblast translocator cDNA, and coevolution with mitochondrial DNA genes. Proc Natl Acad Sci U S A. 1987 Nov;84(21):7580-4.
2829183	Houldsworth J, Attardi G: Two distinct genes for ADP/ATP translocase are expressed at the mRNA level in adult human liver. Proc Natl Acad Sci U S A. 1988 Jan;85(2):377-81.

# Drug_Target_1_HGNC_ID:
HGNC:10990

# Drug_Target_1_HPRD_ID:
00058

# Drug_Target_1_ID:
661

# Drug_Target_1_Locus:
4q35

# Drug_Target_1_Molecular_Weight:
32934

# Drug_Target_1_Name:
ADP/ATP translocase 1

# Drug_Target_1_Number_of_Residues:
297

# Drug_Target_1_PDB_ID:
1OKC

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00153	Mito_carr

# Drug_Target_1_Protein_Sequence:
>ADP/ATP translocase 1
GDHAWSFLKDFLAGGVAAAVSKTAVAPIERVKLLLQVQHASKQISAEKQYKGIIDCVVRI
PKEQGFLSFWRGNLANVIRYFPTQALNFAFKDKYKQLFLGGVDRHKQFWRYFAGNLASGG
AAGATSLCFVYPLDFARTRLAADVGKGAAQREFHGLGDCIIKIFKSDGLRGLYQGFNVSV
QGIIIYRAAYFGVYDTAKGMLPDPKNVHIFVSWMIAQSVTAVAGLVSYPFDTVRRRMMMQ
SGRKGADIMYTGTVDCWRKIAKDEGAKAFFKGAWSNVLRGMGGAFVLVLYDEIKKYV

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Catalyzes the exchange of ADP and ATP across the mitochondrial inner membrane

# Drug_Target_1_SwissProt_ID:
P12235

# Drug_Target_1_SwissProt_Name:
ADT1_HUMAN

# Drug_Target_1_Synonyms:
ADP,ATP carrier protein 1
ADP,ATP carrier protein, heart/skeletal muscle isoform T1
ANT 1
Adenine nucleotide translocator 1
Solute carrier family 25 member 4

# Drug_Target_1_Theoretical_pI:
10.27

# Drug_Target_1_Transmembrane_Regions:
4-38
74-99
108-142
175-201
206-240
272-297

# Drug_Target_2_Cellular_Location:
Mitochondrion
mitochondrial inner membrane
multi-pass membrane protein

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
11961144	Lehenkari PP, Kellinsalmi M, Napankangas JP, Ylitalo KV, Monkkonen J, Rogers MJ, Azhayev A, Vaananen HK, Hassinen IE: Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol Pharmacol. 2002 May;61(5):1255-62.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
SLC25A5

# Drug_Target_2_GenBank_ID_Gene:
M57424

# Drug_Target_2_GenBank_ID_Protein:
178661

# Drug_Target_2_GeneCard_ID:
SLC25A5

# Drug_Target_2_Gene_Name:
SLC25A5

# Drug_Target_2_Gene_Sequence:
>897 bp
ATGACAGATGCCGCTGTGTCCTTCGCCAAGGACTTCCTGGCAGGTGGAGTGGCCGCAGCC
ATCTCCAAGACGGCGGTAGCGCCCATCGAGCGGGTCAAGCTGCTGCTGCAGGTGCAGCAT
GCCAGCAAGCAGATCACTGCAGATAAGCAATACAAAGGCATTATAGACTGCGTGGTCCGT
ATTCCCAAGGAGCAGGGAGTTCTGTCCTTCTGGCGCGGTAACCTGGCCAATGTCATCAGA
TACTTCCCCACCCAGGCTCTTAACTTCGCCTTCAAAGATAAATACAAGCAGATCTTCCTG
GGTGGTGTGGACAAGAGAACCCAGTTTTGGCGCTACTTTGCAGGGAATCTGGCATCGGGT
GGTGCCGCAGGGGCCACATCCCTGTGTTTTGTGTACCCTCTTGATTTTGCCCGTACCCGT
CTAGCAGCTGATGTGGGTAAAGCTGGAGCTGAAAGGGAATTCCGAGGCCTCGGTGACTGC
CTGGTTAAGATCTACAAATCTGATGGGATTAAGGGCCTGTACCAAGGCTTTAACGTGTCT
GTGCAGGGTATTATCATCTACCGAGCCGCCTACTTCGGTATCTATGACACTGCAAAGGGA
ATGCTTCCGGATCCCAAGAACACTCACATCGTCATCAGCTGGATGATCGCACAGACTGTC
ACTGCTGTTGCCGGGTTGACTTCCTATCCATTTGACACCGTTCGCCGCCGCATGATGATG
CAGTCAGGGCGCAAAGGAACTGACATCATGTACACAGGCACGCTTGACTGCTGGCGGAAG
ATTGCTCGTGATGAAGGAGGCAAAGCTTTTTTCAAGGGTGCATGGTCCAATGTTCTCAGA
GGCATGGGTGGTGCTTTTGTGCTTGTCTTGTATGATGAAATCAAGAAGTACACATAA

# Drug_Target_2_General_Function:
Involved in ADP/ATP transporter activity

# Drug_Target_2_General_References:
2168878	Ku DH, Kagan J, Chen ST, Chang CD, Baserga R, Wurzel J: The human fibroblast adenine nucleotide translocator gene. Molecular cloning and sequence. J Biol Chem. 1990 Sep 25;265(27):16060-3.
2829183	Houldsworth J, Attardi G: Two distinct genes for ADP/ATP translocase are expressed at the mRNA level in adult human liver. Proc Natl Acad Sci U S A. 1988 Jan;85(2):377-81.
3031073	Battini R, Ferrari S, Kaczmarek L, Calabretta B, Chen ST, Baserga R: Molecular cloning of a cDNA for a human ADP/ATP carrier which is growth-regulated. J Biol Chem. 1987 Mar 25;262(9):4355-9.

# Drug_Target_2_HGNC_ID:
HGNC:10991

# Drug_Target_2_HPRD_ID:
02147

# Drug_Target_2_ID:
782

# Drug_Target_2_Locus:
Xq24-q26

# Drug_Target_2_Molecular_Weight:
32764

# Drug_Target_2_Name:
ADP/ATP translocase 2

# Drug_Target_2_Number_of_Residues:
297

# Drug_Target_2_PDB_ID:
1OKC

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00153	Mito_carr

# Drug_Target_2_Protein_Sequence:
>ADP/ATP translocase 2
TDAAVSFAKDFLAGGVAAAISKTAVAPIERVKLLLQVQHASKQITADKQYKGIIDCVVRI
PKEQGVLSFWRGNLANVIRYFPTQALNFAFKDKYKQIFLGGVDKRTQFWRYFAGNLASGG
AAGATSLCFVYPLDFARTRLAADVGKAGAEREFRGLGDCLVKIYKSDGIKGLYQGFNVSV
QGIIIYRAAYFGIYDTAKGMLPDPKNTHIVISWMIAQTVTAVAGLTSYPFDTVRRRMMMQ
SGRKGTDIMYTGTLDCWRKIARDEGGKAFFKGAWSNVLRGMGGAFVLVLYDEIKKYT

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Catalyzes the exchange of ADP and ATP across the mitochondrial inner membrane

# Drug_Target_2_SwissProt_ID:
P05141

# Drug_Target_2_SwissProt_Name:
ADT2_HUMAN

# Drug_Target_2_Synonyms:
ADP,ATP carrier protein 2
ADP,ATP carrier protein, fibroblast isoform
ANT 2
Adenine nucleotide translocator 2
Solute carrier family 25 member 5

# Drug_Target_2_Theoretical_pI:
10.23

# Drug_Target_2_Transmembrane_Regions:
4-38
74-99
108-142
175-201
206-240
272-297

# Drug_Target_3_Cellular_Location:
Mitochondrion
mitochondrial inner membrane
multi-pass membrane protein

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
11961144	Lehenkari PP, Kellinsalmi M, Napankangas JP, Ylitalo KV, Monkkonen J, Rogers MJ, Azhayev A, Vaananen HK, Hassinen IE: Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol Pharmacol. 2002 May;61(5):1255-62.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
SLC25A6

# Drug_Target_3_GenBank_ID_Gene:
J03592

# Drug_Target_3_GenBank_ID_Protein:
339723

# Drug_Target_3_GeneCard_ID:
SLC25A6

# Drug_Target_3_Gene_Name:
SLC25A6

# Drug_Target_3_Gene_Sequence:
>897 bp
ATGACGGAACAGGCCATCTCCTTCGCCAAAGACTTCTTGGCCGGAGGCATCGCCGCCGCC
ATCTCCAAGACGGCCGTGGCTCCGATCGAGCGGGTCAAGCTGCTGCTGCAGGTCCAGCAC
GCCAGCAAGCAGATCGCCGCCGACAAGCAGTACAAGGGCATCGTGGACTGCATTGTCCGC
ATCCCCAAGGAGCAGGGCGTGCTGTCCTTCTGGAGGGGCAACCTTGCCAACGTCATTCGC
TACTTCCCCACTCAAGCCCTCAACTTCGCCTTCAAGGATAAGTACAAGCAGATCTTCCTG
GGGGGCGTGGACAAGCACACGCAGTTCTGGAGGTACTTTGCGGGCAACCTGGCCTCCGGC
GGTGCGGCCGGCGCGACCTCCCTCTGCTTCGTGTACCCGCTGGATTTCGCCAGAACCCGC
CTGGCAGCGGACGTGGGAAAGTCAGGCACAGAGCGCGAGTTCCGAGGCCTGGGAGACTGC
CTGGTGAAGATCACCAAGTCCGACGGCATCCGGGGCCTGTACCAGGGCTTCAGTGTCTCC
GTGCAGGGCATCATCATCTACCGGGCGGCCTACTTCGGCGTGTACGATACGGCCAAGGGC
ATGCTCCCCGACCCCAAGAACACGCACATCGTGGTGAGCTGGATGATCGCGCAGACCGTG
ACGGCCGTGGCCGGCGTGGTGTCCTACCCCTTCGACACGGTGCGGCGGCGCATGATGATG
CAGTCCGGGCGCAAAGGAGCTGACATCATGTACACGGGCACCGTCGACTGTTGGAGGAAG
ATCTTCAGAGATGAGGGGGGCAAGGCCTTCTTCAAGGGTGCGTGGTCCAACGTCCTGCGG
GGCATGGGGGGCGCCTTCGTGCTGGTCCTGTACGACGAGCTCAAGAAGGTGATCTAA

# Drug_Target_3_General_Function:
Involved in ATP/ADP transporter activity

# Drug_Target_3_General_References:
2541251	Cozens AL, Runswick MJ, Walker JE: DNA sequences of two expressed nuclear genes for human mitochondrial ADP/ATP translocase. J Mol Biol. 1989 Mar 20;206(2):261-80.
2829183	Houldsworth J, Attardi G: Two distinct genes for ADP/ATP translocase are expressed at the mRNA level in adult human liver. Proc Natl Acad Sci U S A. 1988 Jan;85(2):377-81.

# Drug_Target_3_HGNC_ID:
HGNC:10992

# Drug_Target_3_HPRD_ID:
02461

# Drug_Target_3_ID:
688

# Drug_Target_3_Locus:
Xp22.32 and Yp11.3

# Drug_Target_3_Molecular_Weight:
32735

# Drug_Target_3_Name:
ADP/ATP translocase 3

# Drug_Target_3_Number_of_Residues:
297

# Drug_Target_3_PDB_ID:
1OKC

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF00153	Mito_carr

# Drug_Target_3_Protein_Sequence:
>ADP/ATP translocase 3
TEQAISFAKDFLAGGIAAAISKTAVAPIERVKLLLQVQHASKQIAADKQYKGIVDCIVRI
PKEQGVLSFWRGNLANVIRYFPTQALNFAFKDKYKQIFLGGVDKHTQFWRYFAGNLASGG
AAGATSLCFVYPLDFARTRLAADVGKSGTEREFRGLGDCLVKITKSDGIRGLYQGFSVSV
QGIIIYRAAYFGVYDTAKGMLPDPKNTHIVVSWMIAQTVTAVAGVVSYPFDTVRRRMMMQ
SGRKGADIMYTGTVDCWRKIFRDEGGKAFFKGAWSNVLRGMGGAFVLVLYDELKKVI

# Drug_Target_3_Reaction:
Not Available

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
Catalyzes the exchange of ADP and ATP across the mitochondrial inner membrane. May participate in the formation of the permeability transition pore complex (PTPC) responsible for the release of mitochondrial products that triggers apoptosis

# Drug_Target_3_SwissProt_ID:
P12236

# Drug_Target_3_SwissProt_Name:
ADT3_HUMAN

# Drug_Target_3_Synonyms:
ADP,ATP carrier protein 3
ADP,ATP carrier protein, isoform T2
ANT 3
Adenine nucleotide translocator 2
Solute carrier family 25 member 6

# Drug_Target_3_Theoretical_pI:
10.26

# Drug_Target_3_Transmembrane_Regions:
4-38
74-99
108-142
175-201
206-240
272-297

# Drug_Target_4_Cellular_Location:
Not Available

# Drug_Target_4_Chromosome_Location:
Not Available

# Drug_Target_4_Drug_References:
15803271	Ganguli A, Steward C, Butler SL, Philips GJ, Meikle ST, Lloyd AW, Grant MH: Bacterial adhesion to bisphosphonate coated hydroxyapatite. J Mater Sci Mater Med. 2005 Apr;16(4):283-7.
16046206	Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W, Mangood A, Russell RG, Ebetino FH: Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone. 2006 May;38(5):617-27. Epub 2005 Jul 20.

# Drug_Target_4_Essentiality:
Non-Essential

# Drug_Target_4_GenAtlas_ID:
Not Available

# Drug_Target_4_GenBank_ID_Gene:
Not Available

# Drug_Target_4_GenBank_ID_Protein:
Not Available

# Drug_Target_4_GeneCard_ID:
Not Available

# Drug_Target_4_Gene_Name:
Not Available

# Drug_Target_4_Gene_Sequence:
Not Available

# Drug_Target_4_General_Function:
Hydroxylapatite is the main mineral component of bone. Carbonated-calcium deficient hydroxyapatite is the main mineral of which dental enamel and dentin are comprised.

# Drug_Target_4_General_References:
Not Available

# Drug_Target_4_HGNC_ID:
Not Available

# Drug_Target_4_HPRD_ID:
Not Available

# Drug_Target_4_ID:
930

# Drug_Target_4_Locus:
Not Available

# Drug_Target_4_Molecular_Weight:
502.311

# Drug_Target_4_Name:
Hydroxyapatite

# Drug_Target_4_Number_of_Residues:
0

# Drug_Target_4_PDB_ID:
Not Available

# Drug_Target_4_Pathway:
Not Available

# Drug_Target_4_Pfam_Domain_Function:
Not Available

# Drug_Target_4_Protein_Sequence:
Not Available

# Drug_Target_4_Reaction:
Not Available

# Drug_Target_4_Signals:
Not Available

# Drug_Target_4_Specific_Function:
Not Available

# Drug_Target_4_SwissProt_ID:
Not Available

# Drug_Target_4_SwissProt_Name:
Not Available

# Drug_Target_4_Synonyms:
Not Available

# Drug_Target_4_Theoretical_pI:
Not Available

# Drug_Target_4_Transmembrane_Regions:
Not Available

#END_DRUGCARD DB00720
